Medinice has a patent in South Korea on the camula for minimally invasive cannulation of the vena cava

Medinice has received a patent from the South Korean Patent Office for a transcutaneous minimally invasive vena cava cannula, the company said. The final formal requirement for obtaining a patent is the payment of an administrative fee.
"The aim of the project is to develop a cannula for percutaneous minimally invasive vena cava cannulation, which will optimize blood circulation during extracorporeal circulation, especially in the upper body, and to perform the procedure using the percutaneous method, which is a less invasive, more effective, cheaper and faster method," reads the release.

Medinice is a Polish company with a global reach, being a platform for solutions used in cardiology. The company develops its own projects and projects obtained from scientists from Poland and abroad. The team consists of professionals in the field of medicine, clinical trials, law (in particular intellectual property) and finance. The company made its debut on the WSE main market in December 2020.

Our privacy policy